Porcine Insulin Zinc Injection

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
1
Deaths Reported
620.0%
Death Rate

Active Ingredients

Porcine Insulin Zinc Injection

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Cat 9
Dog 7

Most Affected Breeds

Domestic Shorthair 6
Shih Tzu 1
Crossbred Canine/dog 1
Retriever - Labrador 1
Shepherd Dog - Australian 1
Cat (unknown) 1
Domestic Longhair 1
Brittany 1
Poodle - Miniature 1
Domestic Mediumhair 1

Most Reported Reactions

Lack of efficacy - NOS 5
Ketosis 4
Lethargy (see also Central nervous system depression in Neurological) 4
Weight loss 4
Walking difficulty 2
Not eating 2
Hiding 2
Polydipsia 2
Polyuria 2
Hypoglycaemia 2
Hyperglycaemia 2
Weight gain 1

Outcome Breakdown

Ongoing
8 (50.0%)
Outcome Unknown
5 (31.3%)
Recovered with Sequela
1 (6.3%)
Recovered/Normal
1 (6.3%)
Died
1 (6.3%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 1
Case-fatality rate (reported events) 620.0%
Distinct species in reports 2
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Porcine Insulin Zinc Injection Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Porcine Insulin Zinc Injection, including 1 reports in which the animal died — a 620.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Porcine Insulin Zinc Injection. Reported administration routes include Unknown, Subcutaneous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Porcine Insulin Zinc Injection reports are Cat (9 reports), Dog (7 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (6), Shih Tzu (1), Crossbred Canine/dog (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Porcine Insulin Zinc Injection are Lack of efficacy - NOS (5), Ketosis (4), Lethargy (see also Central nervous system depression in Neurological) (4), Weight loss (4). Of the 16 reports with a coded outcome, Ongoing is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Porcine Insulin Zinc Injection.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial